Company family · HQ US
Biogen: medicine shortages
BIIB · Nasdaq
As of 2 Nov 2026, 3 Biogen products have a reported shortage across 3 countries, covering 3 medicines.
Products short3rank #393 of 464
Medicines3active ingredients
Countries3/16
New in 90 days00 vs market pace
Typical duration2.1 yearsmedian so far
Manufacturing0%demand-driven 0%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Daclizumab | 1 | not given | Not stated | 1/16 | |
| Dimethyl Fumarate | 1 | 16 Feb 2024 | Other | 5/16 | |
| Metformin and Sulfonylureas | 1 | 1 Jun 2025 | Commercial decision or withdrawal | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.